DealSite reported that Bridge Biotherapeutics has changed its name and shifted its focus to a digital asset treasury business. The bio-new drug development company, once highly anticipated for its large-scale technology transfer achievements, has been reorganized into 'Parataxis Korea' after its key pipeline was abandoned, followed by a sale of management rights and business restructuring.
